Related Experiment Video
Updated: May 19, 2026
12:24
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Genomic variation-guided management in chronic hepatitis C
Ching-Sheng Hsu1, Jia-Horng Kao
1Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch, Taiwan.
Expert Review of Gastroenterology & Hepatology
|August 30, 2012
Summary
Genome-wide association studies identified IL28B gene polymorphisms as predictors of treatment response in chronic hepatitis C (CHC) patients. These genetic variations also impact hepatitis C virus (HCV) clearance and ribavirin treatment outcomes.
Area of Science:
- Genetics
- Hepatology
- Virology
Background:
- Chronic hepatitis C (CHC) management has been revolutionized by genetic discoveries.
- Genome-wide association studies (GWAS) have identified key genetic predictors for treatment response.
- IL28B gene polymorphisms are crucial for predicting interferon-based treatment outcomes in CHC patients.
Purpose of the Study:
- To review advances in GWAS for hepatitis C virus (HCV) infection.
- To discuss the impact of genetic variations on CHC management.
- To explore the clinical utility of genomic variations with direct antiviral agents.
Main Methods:
- Genome-wide association studies (GWAS).
- Analysis of genetic variations (polymorphisms) near the IL28B and ITPA genes.
- Review of existing literature on genetic associations with HCV infection and treatment.
Main Results:
- IL28B gene polymorphisms predict therapeutic response in CHC patients receiving interferon.
- Genetic variations are strongly associated with spontaneous viral clearance of HCV.
- ITPA gene variants influence ribavirin-induced anemia and CHC treatment outcomes.
Conclusions:
- Genomic insights have ushered in a new era for HCV management.
- Genetic variations play a significant role in predicting treatment efficacy and adverse events.
- Further research is needed to integrate genomic data with direct antiviral agents for optimized CHC care.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...